Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma Group to secure potential U.S. commercial rights and global manufacturing rights for alvelestat, an investigational therapy being developed for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
The agreement gives Sentynl, a wholly owned subsidiary of Zydus Lifesciences, the exclusive option to acquire a license to commercialize alvelestat in the United States. Mereo will retain commercial rights in markets outside the U.S., while Sentynl would take responsibility for global manufacturing of the medicine for AATD-LD if the option is exercised.
The transaction highlights the commercial interest surrounding biopharmaceutical programmes targeting rare genetic diseases, particularly those approaching late-stage clinical development. Alvelestat is a neutrophil elastase inhibitor preparing to enter Phase 3 development and, if approved, could become the first oral treatment specifically for AATD-LD.
AATD-LD is a rare inherited disorder caused by mutations affecting alpha-1 antitrypsin, a protein that helps protect lung tissue from damage. The condition can progressively impair lung function and is associated with substantial long-term morbidity. Mereo estimates that between 50,000 and 80,000 people in the U.S. are affected.
For Sentynl, the agreement expands its focus on rare diseases while giving Mereo access to a partner with an established commercial infrastructure in the U.S. The companies will work together during the option period on manufacturing activities and the design of the planned Phase 3 programme.
Alvelestat Moves Toward Phase 3 Development
Alvelestat is designed to inhibit neutrophil elastase, an enzyme involved in inflammation and tissue damage. In AATD-LD, insufficient levels of functional alpha-1 antitrypsin can leave lung tissue more vulnerable to the damaging effects of neutrophil elastase.
The investigational medicine is being developed as an oral therapy, a feature that could distinguish it from existing management approaches if clinical development and regulatory review are successful.
Mereo plans to lead the global Phase 3 study and manage regulatory interactions through completion of the trial. The companies expect the Phase 3 programme could begin as early as the first quarter of 2027, although the timing will depend on further development and regulatory planning.
The option structure also allows both companies to refine the development strategy before Sentynl makes a final decision on exercising its commercial license rights. During this period, Mereo and Sentynl will work on manufacturing plans and the design of the global Phase 3 study.
The companies have not disclosed detailed Phase 3 trial parameters, but the agreement indicates that preparation for the late-stage programme is already becoming a central priority.
For patients, the potential significance of alvelestat lies in the limited treatment landscape for AATD-LD. The disease can progress over many years and may eventually result in severe impairment of respiratory function. An oral disease-targeted treatment could provide an additional option if the therapy demonstrates meaningful clinical benefit.
Dr. Sharvil P. Patel, managing director of Zydus Lifesciences, said the partnership represents an important step in Sentynl’s rare disease strategy and described alvelestat as a differentiated candidate addressing a significant unmet medical need.
Mereo Chief Executive Officer Denise Scots-Knight said Sentynl’s rare disease focus and U.S. commercial infrastructure made it a suitable partner for the programme.
The partnership therefore combines two different strengths. Mereo brings ownership of the development programme and expertise in the rare disease, while Sentynl provides a potential route to U.S. commercialization and global manufacturing.
Deal Structure Creates Milestone Opportunity for Mereo
Financial terms provide Mereo with an immediate option fee that will not be refundable. If Sentynl exercises the option, Mereo could receive up to $40 million in upfront and research and development payments through the filing of a New Drug Application with the U.S. Food and Drug Administration.
Mereo would also become eligible for tiered royalties in the double-digit range on net U.S. sales of alvelestat.
The structure gives Mereo a potential source of funding for the next stage of development while preserving its commercial rights outside the United States. For Sentynl, the arrangement provides an opportunity to secure access to a potential rare disease product before Phase 3 development begins without immediately assuming the full commercial commitment.
The agreement also gives manufacturing a prominent role. Sentynl will receive global manufacturing rights for alvelestat for AATD-LD, while both companies collaborate on manufacturing preparations during the option period.
Manufacturing can be particularly important for rare disease therapies because commercial supply requirements may differ substantially from those of high-volume medicines. Establishing production processes ahead of a potential regulatory filing can help reduce later operational challenges.
For Sentynl, the deal fits with a broader strategy of building a portfolio in areas where specialized medicines can address substantial unmet needs. Its connection to Zydus Lifesciences also provides the company with access to the resources of a larger pharmaceutical group.
For Mereo, the agreement offers a potential route to commercialization without giving up its international rights. The company will continue to lead the global Phase 3 programme and regulatory engagement while using the partnership to prepare for manufacturing and development requirements.
The next major milestone will be the finalization of the Phase 3 programme. During the option period, the companies are expected to refine the study design and determine the operational requirements needed to launch the trial.
If Sentynl ultimately exercises the option, the transaction could mark a significant transition for alvelestat from a late-stage investigational asset toward a potential commercial product.
The opportunity is also closely tied to the broader development of rare disease medicines. With an estimated tens of thousands of patients in the U.S. and limited disease-specific treatment options, AATD-LD represents a niche market with significant medical need.
Alvelestat still faces the clinical and regulatory hurdles associated with any investigational therapy, and approval is not guaranteed. However, the agreement places the programme on a clearer path toward Phase 3 while giving both companies defined roles in its potential development and commercialization.
For Mereo, the partnership provides financial and operational support at a critical stage. For Sentynl, it creates an opportunity to add a potentially first-in-class oral treatment to its rare disease portfolio. The outcome will ultimately depend on whether alvelestat can translate its development rationale into positive Phase 3 results and regulatory approval.
Ref: https://www.contractpharma.com/breaking-news/sentynl-secures-u-s-rights-to-mereos-alvelestat/
